384 related articles for article (PubMed ID: 24248188)
21. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
22. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.
Adeniran AJ; Zhu Z; Gandhi M; Steward DL; Fidler JP; Giordano TJ; Biddinger PW; Nikiforov YE
Am J Surg Pathol; 2006 Feb; 30(2):216-22. PubMed ID: 16434896
[TBL] [Abstract][Full Text] [Related]
23. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
24. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
[TBL] [Abstract][Full Text] [Related]
25. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
26. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.
Leeman-Neill RJ; Brenner AV; Little MP; Bogdanova TI; Hatch M; Zurnadzy LY; Mabuchi K; Tronko MD; Nikiforov YE
Cancer; 2013 May; 119(10):1792-9. PubMed ID: 23436219
[TBL] [Abstract][Full Text] [Related]
27. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
28. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
[TBL] [Abstract][Full Text] [Related]
29. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
30. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
31. Modifications in the papillary thyroid cancer gene profile over the last 15 years.
Romei C; Fugazzola L; Puxeddu E; Frasca F; Viola D; Muzza M; Moretti S; Nicolosi ML; Giani C; Cirello V; Avenia N; Rossi S; Vitti P; Pinchera A; Elisei R
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1758-65. PubMed ID: 22745248
[TBL] [Abstract][Full Text] [Related]
32. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
[TBL] [Abstract][Full Text] [Related]
33. Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment.
Boaventura P; Pereira D; Celestino R; Mendes A; Nakasawa T; Teixeira-Gomes J; Sobrinho-Simões M; Soares P
Eur J Endocrinol; 2013 Nov; 169(5):673-9. PubMed ID: 23966419
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
36. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R
Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674
[TBL] [Abstract][Full Text] [Related]
37. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
39. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
40. Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.
Kakarmath S; Heller HT; Alexander CA; Cibas ES; Krane JF; Barletta JA; Lindeman NI; Frates MC; Benson CB; Gawande AA; Cho NL; Nehs M; Moore FD; Marqusee E; Kim MI; Larsen PR; Kwong N; Angell TE; Alexander EK
J Clin Endocrinol Metab; 2016 Dec; 101(12):4938-4944. PubMed ID: 27689252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
